HRMY Q3 2025 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$239M+28.7% YoY

Gross Profit

$180M75.1% margin

Operating Income

$65M27.3% margin

Net Income

$51M21.2% margin

EPS (Diluted)

$0.87

QoQ Revenue Growth

+19.4%

Cash Flow

Operating Cash Flow

$109M

Free Cash Flow

$109M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$373M

Stockholders' Equity

$835M

Cash & Equivalents

$647M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$239M	$186M	+28.7%
Gross Profit	$180M	$143M	+25.5%
Operating Income	$65M	$62M	+6.1%
Net Income	$51M	$46M	+10.4%